Fast Five Quiz: Type 2 Diabetes Incretin-Based Therapy

Romesh Khardori, MD, PhD; Anne L. Peters, MD


May 16, 2022

Figure 1. Glucagon-like peptide 1 (GLP1, 7-36) molecule. GLP-1 analogues are used in the treatment of diabetes.

Guidelines from the American Association of Clinical Endocrinology recommend considering GLP-1 receptor agonists (RAs) in combination with metformin for patients who have not reached their glycemic target. Research has shown that GLP-1 RAs are the most effective non-insulin agent in reducing hemoglobin A1c in patients with uncontrolled type 2 diabetes. Incretin-based therapy can also be considered in patients with contraindications to metformin, such as of renal dysfunction. Data have shown that incretin-based therapies can improve glycemic efficacy alone or in combination with other oral antidiabetic drugs.

Learn more about type 2 diabetes.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.